Anti-PDL1 antibodies and methods of use
By developing high-affinity single-domain antibodies and multi-specific antibodies, the lack of effective methods to target PDL1 in existing technologies has been solved, achieving targeted targeting of tumor cells and enhanced immune response, thereby improving anti-tumor efficacy.
Patent Information
- Application Number
- JP2025538457
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-29
- Filing Date
- 2023-12-29
- Publication Date
- 2026-01-08
AI Technical Summary
There is a lack of effective molecules and methods in the current technology to target PDL1 to treat cancer, block the PD1/PDL1 interaction to activate the immune response, and enhance anti-tumor activity.
High-affinity single-domain antibodies and multi-specific antibodies have been developed that can specifically bind to PDL1 and bind to other targets to enhance the immune response to attack tumor cells. These include single-domain antibodies and multi-specific antibodies that enhance the anti-tumor effect by binding to PDL1 and enhancing the immune response.
It improves the ability to target tumor cells and the immune response, enhancing the anti-tumor effect, and showing significant therapeutic potential, especially in cancers with high microsatellite instability.
Smart Images
Figure 2026500778000017 
Figure 2026500778000018 
Figure 2026500778000019